BioCentury | Aug 4, 2020
Product Development

Aug. 3 Quick Takes: CymaBay gains on PBC readout; plus expanded labels for Epidiolex, Spravato, Voyager-AbbVie deal ends, Immunic and more

CymaBay plans to re-start pivotal trial  Shares of CymaBay Therapeutics Inc. (NASDAQ:CBAY) rose $1.33 (37%) to $4.88 Monday after 78.2% of primary biliary cholangitis (PBC) patients on its seladelpar met the primary composite outcome of...
BioCentury | Jun 20, 2020
Deals

Clinical scorecard for COVID-19: lessons from the first wave of controlled trials

Breaking through the noise of poor-quality clinical studies are the first clear signals of a treatment paradigm for COVID-19, indicating how and when to use the two major therapeutic approaches -- attacking the virus and...
BioCentury | Jun 12, 2020
Finance

May’s momentum continues as Catalent, eight others price follow-ons

The follow-on market has shown no signs of slowing down. More than $1.3 billion in follow-on capital has been raised so far this week, bringing the month’s total raise to nearly $4 billion. While the...
BioCentury | May 15, 2020
Product Development

Repurposed autoimmune therapies head for controlled COVID-19 studies in Europe

Abivax and Immunic are launching COVID-19 trials of their autoimmune therapies in France and Germany, respectively, meeting regulators’ demands for large, controlled studies to demonstrate therapeutic efficacy. In the U.S., the patent office is fast-tracking...
BioCentury | Apr 22, 2020
Management Tracks

Hershberg joins Frazier as venture partner; plus Moses to chair LabGenius, and ViralClear, MorphoSys, Emergent and more

Robert Hershberg has joined Frazier Healthcare Partners as venture partner. The former EVP, CSO and head of BD and global alliances of Celgene Corp. helped coordinate the company’s $74 billion takeout by Bristol Myers Squibb...
BC Extra | Jul 19, 2019
Company News

Management tracks: Iovance, ViiV, Hercules, Pappas and more

Cancer immunotherapy company Iovance Biotherapeutics Inc. (NASDAQ:IOVA) hired Friedrich Graf Finckenstein as CMO. He was global head of oncology translational medicine of the Pharma Research and Early Development (pRED) unit of Roche (SIX:ROG; OTCQX:RHHBY). ViiV...
BC Extra | May 8, 2019
Company News

Management tracks: Immunocore, Kyn, Engitix

Immunocore Ltd. (Abingdon, U.K.) brought on a third ex-AstraZeneca plc (LSE:AZN; NYSE:AZN) executive, hiring Mohammed Dar as head of clinical development and CMO. Dar was VP, clinical development oncology, R&D at AZ's MedImmune LLC subsidiary....
BC Week In Review | Jan 11, 2019
Company News

Immunic plans to go public via Vital Therapies

Vital Therapies Inc. (NASDAQ:VTL) will acquire all outstanding shares of Immunic AG (Martinsried, Germany). The resulting company, which will retain Immunic's name and trade on NASDAQ, will develop Immunic’s pipeline, including IMU-838, a molecule inhibitor...
BC Week In Review | Nov 30, 2018
Company News

Immunic gets rights to Daiichi's IBD candidates

Daiichi Sankyo Co. Ltd. (Tokyo:4568) granted Immunic AG (Martinsried, Germany) exclusive, worldwide rights to a group of inflammatory bowel disease candidates against an undisclosed target. Immunic said animal studies suggest the target could be disease...
BC Week In Review | Sep 8, 2017
Financial News

Immunic tops off EUR31.7M series A

Immunic AG (Planegg-Martinsried, Germany) raised an additional €10 million ($11.9 million) in a series A round on Sept. 5, bringing the total raised to €31.7 million ($37.7 million). New investors Omega Funds and Fund+ participated....
Items per page:
1 - 10 of 16
BioCentury | Aug 4, 2020
Product Development

Aug. 3 Quick Takes: CymaBay gains on PBC readout; plus expanded labels for Epidiolex, Spravato, Voyager-AbbVie deal ends, Immunic and more

CymaBay plans to re-start pivotal trial  Shares of CymaBay Therapeutics Inc. (NASDAQ:CBAY) rose $1.33 (37%) to $4.88 Monday after 78.2% of primary biliary cholangitis (PBC) patients on its seladelpar met the primary composite outcome of...
BioCentury | Jun 20, 2020
Deals

Clinical scorecard for COVID-19: lessons from the first wave of controlled trials

Breaking through the noise of poor-quality clinical studies are the first clear signals of a treatment paradigm for COVID-19, indicating how and when to use the two major therapeutic approaches -- attacking the virus and...
BioCentury | Jun 12, 2020
Finance

May’s momentum continues as Catalent, eight others price follow-ons

The follow-on market has shown no signs of slowing down. More than $1.3 billion in follow-on capital has been raised so far this week, bringing the month’s total raise to nearly $4 billion. While the...
BioCentury | May 15, 2020
Product Development

Repurposed autoimmune therapies head for controlled COVID-19 studies in Europe

Abivax and Immunic are launching COVID-19 trials of their autoimmune therapies in France and Germany, respectively, meeting regulators’ demands for large, controlled studies to demonstrate therapeutic efficacy. In the U.S., the patent office is fast-tracking...
BioCentury | Apr 22, 2020
Management Tracks

Hershberg joins Frazier as venture partner; plus Moses to chair LabGenius, and ViralClear, MorphoSys, Emergent and more

Robert Hershberg has joined Frazier Healthcare Partners as venture partner. The former EVP, CSO and head of BD and global alliances of Celgene Corp. helped coordinate the company’s $74 billion takeout by Bristol Myers Squibb...
BC Extra | Jul 19, 2019
Company News

Management tracks: Iovance, ViiV, Hercules, Pappas and more

Cancer immunotherapy company Iovance Biotherapeutics Inc. (NASDAQ:IOVA) hired Friedrich Graf Finckenstein as CMO. He was global head of oncology translational medicine of the Pharma Research and Early Development (pRED) unit of Roche (SIX:ROG; OTCQX:RHHBY). ViiV...
BC Extra | May 8, 2019
Company News

Management tracks: Immunocore, Kyn, Engitix

Immunocore Ltd. (Abingdon, U.K.) brought on a third ex-AstraZeneca plc (LSE:AZN; NYSE:AZN) executive, hiring Mohammed Dar as head of clinical development and CMO. Dar was VP, clinical development oncology, R&D at AZ's MedImmune LLC subsidiary....
BC Week In Review | Jan 11, 2019
Company News

Immunic plans to go public via Vital Therapies

Vital Therapies Inc. (NASDAQ:VTL) will acquire all outstanding shares of Immunic AG (Martinsried, Germany). The resulting company, which will retain Immunic's name and trade on NASDAQ, will develop Immunic’s pipeline, including IMU-838, a molecule inhibitor...
BC Week In Review | Nov 30, 2018
Company News

Immunic gets rights to Daiichi's IBD candidates

Daiichi Sankyo Co. Ltd. (Tokyo:4568) granted Immunic AG (Martinsried, Germany) exclusive, worldwide rights to a group of inflammatory bowel disease candidates against an undisclosed target. Immunic said animal studies suggest the target could be disease...
BC Week In Review | Sep 8, 2017
Financial News

Immunic tops off EUR31.7M series A

Immunic AG (Planegg-Martinsried, Germany) raised an additional €10 million ($11.9 million) in a series A round on Sept. 5, bringing the total raised to €31.7 million ($37.7 million). New investors Omega Funds and Fund+ participated....
Items per page:
1 - 10 of 16